Bank of New York Mellon Corp Boosts Holdings in Balchem Co. (NASDAQ:BCPC)

Bank of New York Mellon Corp raised its holdings in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 243,627 shares of the basic materials company's stock after acquiring an additional 2,025 shares during the period. Bank of New York Mellon Corp owned approximately 0.75% of Balchem worth $39,710,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BCPC. Watts Gwilliam & Co. LLC boosted its holdings in Balchem by 63.7% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company's stock valued at $5,438,000 after purchasing an additional 13,642 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Balchem by 1.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company's stock worth $80,782,000 after purchasing an additional 7,721 shares during the period. Stifel Financial Corp lifted its stake in shares of Balchem by 26.2% in the 3rd quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company's stock valued at $2,093,000 after purchasing an additional 2,467 shares during the period. Apollon Wealth Management LLC purchased a new stake in Balchem during the fourth quarter worth $503,000. Finally, Congress Asset Management Co. increased its holdings in Balchem by 5.4% in the fourth quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company's stock valued at $51,769,000 after buying an additional 16,170 shares in the last quarter. Institutional investors and hedge funds own 87.91% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

BCPC has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $190.00 price objective on shares of Balchem in a report on Monday, February 24th. Sidoti raised shares of Balchem to a "hold" rating in a research note on Tuesday, February 25th. Finally, StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th.

Balchem Price Performance

NASDAQ BCPC traded down $5.10 during mid-day trading on Monday, hitting $170.59. The stock had a trading volume of 273,423 shares, compared to its average volume of 138,889. Balchem Co. has a twelve month low of $137.69 and a twelve month high of $186.03. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of 43.41, a PEG ratio of 4.41 and a beta of 0.63. The firm's 50 day moving average is $163.17 and its 200 day moving average is $169.84. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16.

Balchem (NASDAQ:BCPC - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). The business had revenue of $240.00 million for the quarter, compared to analyst estimates of $239.96 million. Balchem had a return on equity of 11.37% and a net margin of 13.47%. Equities research analysts forecast that Balchem Co. will post 4.64 earnings per share for the current fiscal year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.